Shares of Dr. Reddy’s Laboratories Ltd. (NYSE:RDY) were up 2.8% on Monday . The company traded as high as $44.86 and last traded at $44.86, with a volume of 210,947 shares changing hands. The stock had previously closed at $43.65.

A number of research firms have recently commented on RDY. HSBC cut Dr. Reddy’s Laboratories from a “hold” rating to a “reduce” rating in a report on Wednesday, July 27th. Zacks Investment Research cut Dr. Reddy’s Laboratories from a “buy” rating to a “strong sell” rating in a report on Thursday, July 28th. Credit Suisse Group AG cut Dr. Reddy’s Laboratories from a “neutral” rating to an “underperform” rating in a report on Tuesday, July 26th. Jefferies Group cut Dr. Reddy’s Laboratories from a “hold” rating to an “underperform” rating and lowered their target price for the stock from $45.00 to $41.90 in a report on Wednesday, July 27th. Finally, Goldman Sachs Group Inc. initiated coverage on Dr. Reddy’s Laboratories in a report on Monday, May 2nd. They issued a “neutral” rating for the company. Five research analysts have rated the stock with a sell rating, three have assigned a hold rating and one has given a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average price target of $51.45.

The company’s 50 day moving average price is $49.43 and its 200-day moving average price is $46.24. The company has a market cap of $7.52 billion and a PE ratio of 33.64.

Dr. Reddy’s Laboratories (NYSE:RDY) last posted its quarterly earnings results on Tuesday, July 26th. The company reported $0.00 EPS for the quarter. The company earned $479 million during the quarter, compared to the consensus estimate of $557 million. Equities research analysts expect that Dr. Reddy’s Laboratories Ltd. will post $1.69 earnings per share for the current fiscal year.

The business also recently declared an annual dividend, which was paid on Monday, July 18th. Stockholders of record on Monday, July 18th were issued a $0.277 dividend. The ex-dividend date was Thursday, July 14th.

Other large investors have bought and sold shares of the company. OppenheimerFunds Inc. raised its stake in Dr. Reddy’s Laboratories by 10.5% in the fourth quarter. OppenheimerFunds Inc. now owns 37,908 shares of the company’s stock valued at $1,755,000 after buying an additional 3,600 shares in the last quarter. Principal Financial Group Inc. raised its stake in Dr. Reddy’s Laboratories by 99.8% in the fourth quarter. Principal Financial Group Inc. now owns 492,288 shares of the company’s stock valued at $22,788,000 after buying an additional 245,913 shares in the last quarter. Advisors Asset Management Inc. raised its stake in Dr. Reddy’s Laboratories by 3.2% in the fourth quarter. Advisors Asset Management Inc. now owns 43,693 shares of the company’s stock valued at $2,023,000 after buying an additional 1,341 shares in the last quarter. Finally, Morgan Stanley raised its stake in Dr. Reddy’s Laboratories by 366.0% in the fourth quarter. Morgan Stanley now owns 308,997 shares of the company’s stock valued at $14,303,000 after buying an additional 242,689 shares in the last quarter.

Dr. Reddy’s Laboratories Limited is an integrated global pharmaceutical company that is engaged in providing medicines. The Company operates in three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. Global Generics segment consists of its business of manufacturing and marketing prescription and over-the-counter (OTC) finished pharmaceutical products, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.